News & Podcast
Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.

Solve for Tomorrow: Ideen gesucht!
Apply now: Solve for Tomorrow is looking for ideas in the areas of health, sustainability, and social inclusion. The application deadline for the funding program runs until June 23, 2026.

Fresenius invests in Munich healthtech startup Avelios Medical
Fresenius is joining Avelios Medical and thus expanding the technology partnership between the Munich healthtech startup and SAP that launched in February. The goal is to build an open, interoperable, and AI-native digital healthcare ecosystem for Europe. The core platform is the Avelios hospital information system.

Rnatics: Hope in pulmonary fibrosis
Rnatics is developing RCS-21, a novel inhalable drug against lung inflammation and idiopathic pulmonary fibrosis. The startup was founded in 2021 as a spin-off from TUM by Stefan Engelhardt together with Thomas Frischmuth and Klaus Rabe. After promising research and ongoing clinical studies, the team aims to reach the next milestones and create new therapy options for patients. Clinical lead and pharmacist with a PhD, Christina Beck, explains the details about the founding and mission to us.

Tubulis acquired by American pharma giant
Munich-based biotech unicorn Tubulis is being acquired by US company Gilead for a multibillion-euro amount.

Rnhale: Inhalable RNA for new therapies
The Munich-based biotech startup Rnhale develops inhalable RNA therapeutics as dry powder – faster, simpler, and more efficient than previous approaches. This is intended to treat respiratory diseases such as COPD or asthma in a targeted manner. CEO Benjamin Winkeljann explains in an interview why the path from research to product is challenging and what hurdles almost caused them to fail.

Mpiriq: AI connects healthcare and research
Mpiriq connects medical healthcare and research using artificial intelligence. The platform structures data from practices and hospitals, automates documentation and thus enables faster studies and better therapies – without additional effort in daily work. The team explains how it works and why trust is crucial in an interview.

SAP invests in Avelios Medical
Munich-based software provider Avelios Medical receives a strategic investment from SAP. Together, the partners are developing a new digital platform for hospitals, responding to the planned replacement of central IT systems in the clinical market.

Milestone in treating lung disease? Rnatics secures €2.7 million
The Munich biotech startup Rnatics secures €2.7 million in federal funding. The funds will support clinical development of an inhalable RNA therapeutic for inflammatory and fibrotic lung diseases.

Custom Surgical raises funding for digitalization of ophthalmology
Munich-based medtech startup Custom Surgical receives 3.5 million euros from Ventech, Zeiss, and other investors. With the pre-Series A round, the company is advancing the digitalization of workflows in ophthalmology and its international expansion.

Smartbax: New antibiotics against superbugs
Smartbax develops innovative antibiotics against multidrug-resistant bacteria with a completely new mechanism of action: instead of blocking processes, they cause pathogens to self-destruct. Emerging from research at TU München, the startup is working on clinical trials while fighting against the resistance crisis and market hurdles.

Bodyfast secures strategic investment
Munich-based healthtech Bodyfast is securing its first strategic investor with Isartal Health Media. The investment by Wort & Bild publishing group marks the next growth milestone for the intermittent fasting app.

Cellbyte: AI accelerates market access for pharma
Cellbyte wants to revolutionize the global market launch of medicines: with an AI-native platform, the Munich startup automates pricing and market access processes in the pharmaceutical industry. Over 100 data sources, deep industry knowledge, and regulatory expertise enable complex decisions in seconds.